<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Bioengineered systems - Medium]]></title>
        <description><![CDATA[Join us in communicating the science and business of smart protein, cellular agriculture and future food/biomaterials. Reach out to tarika@trovebiosciences.com - Medium]]></description>
        <link>https://medium.com/bioengineered-systems?source=rss----8623283b878f---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>Bioengineered systems - Medium</title>
            <link>https://medium.com/bioengineered-systems?source=rss----8623283b878f---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 22:37:20 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/bioengineered-systems" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Investing in Enabling Technologies in Biotech — Part II]]></title>
            <link>https://medium.com/bioengineered-systems/investing-in-enabling-technologies-in-biotech-part-ii-89455ab71db6?source=rss----8623283b878f---4</link>
            <guid isPermaLink="false">https://medium.com/p/89455ab71db6</guid>
            <category><![CDATA[synthetic-biology]]></category>
            <category><![CDATA[bioeconomy]]></category>
            <category><![CDATA[investment-thesis]]></category>
            <category><![CDATA[bio-manufacturing]]></category>
            <dc:creator><![CDATA[Tarika Vijayaraghavan, Ph.D. ]]></dc:creator>
            <pubDate>Sun, 24 Nov 2024 22:57:32 GMT</pubDate>
            <atom:updated>2024-11-24T22:14:52.073Z</atom:updated>
            <content:encoded><![CDATA[<h3>Investing in Enabling Technologies in Biotech — Part II</h3><p>An *imaginary* VC fund and a biotech company walk into a bar …</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*5df-6Kemrb1PqAWL" /><figcaption>Photo by <a href="https://unsplash.com/@dafidvor?utm_source=medium&amp;utm_medium=referral">David Dvořáček</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><p>In the <a href="https://medium.com/bioengineered-systems/investing-in-enabling-technologies-in-biotech-part-1-7be97c0e0831">first part of this topic</a>, we looked into the landscape of enabling technologies, including reasons to invest, interesting segments and the key players within them.</p><p>In this article, we will dive deeper into understanding how VCs invest in a company by using a hypothetical venture capital firm — BowTie Venture Fund and a biotech startup, Scythe Bio, as a case study.</p><p>A general glossary of VC terms laid out by <a href="https://medium.com/u/1a206ce5f09a">Bread and Butter Ventures</a> can be found <a href="https://medium.com/p/48c3aa8f8cd7">here</a>.</p><p>Disclaimer: This article serves as an exercise to provide an analysis from the perspective of a hypothetical VC fund investing in a hypothetical biotech company. As such, it does not aim to give any investment advice or recommendation.</p><h4>Mandate: BowTie Ventures</h4><p>BowTie Venture Fund (hereafter referred to as BowTie VC) invests in enabling technologies within bioengineered foods, biomaterials, and chemicals, focusing on solutions that eliminate animal-derived components and align with COP28 and global sustainability goals. We target early-stage, B2B companies (Seed to Series B) with strong Intellectual Property (IP), experienced technical teams, and a clear revenue path within 12 months of investment.</p><p>The bioengineered food and biomaterials sectors offer vast growth potential, driven by advancements in synthetic biology and strain engineering, with a projected market cap exceeding $300 billion. Rising carbon taxes and shifting toward sustainable practices are accelerating the demand for alternative proteins and precision fermentation.</p><h4>Thesis Focus and Scope</h4><p>This investment thesis centers on enabling technologies that <strong><em>remove or replace</em></strong> animal-derived products through synthetic biology, fermentation platforms, metabolic engineering, and other bioprocessing innovations. The goal is to invest in portfolio companies offering food, materials, and chemicals that provide equal or superior value in taste, nutrition, or economics compared to traditional products without relying on animals at any stage.</p><p><strong>Excluded sectors:</strong> Traditional agricultural methods, feed technologies, and companies using insects, poultry, marine animals, or mammals as inputs.</p><h3>Criteria for Investment</h3><p>We seek companies that exhibit the following attributes:</p><ol><li><strong>Animal-free solutions:</strong> Must aim to eliminate or replace animal-derived products in food or material production.</li><li><strong>Strong IP Protection:</strong> Competitive technology differentiation secured through patents and trade secrets.</li><li><strong>Technical and Business Team Strength:</strong> Well-rounded teams with both R&amp;D expertise and business development skills to drive growth.</li><li><strong>B2B Model or Strong Business Moat (if B2C</strong>): Companies with diversified customer bases across multiple industries or deep market advantages.</li><li><strong>Revenue-generating or Near-Revenue:</strong> Clear path to revenue generation within 12 months of investment.</li><li><strong>Pre-seed to Series B Stage:</strong> Focus on early- to mid-stage companies ready for commercial scaling.</li><li><strong>Versatile Market Applications:</strong> Solutions should appeal to diverse customers, spanning multiple industries (e.g., food, cosmetics, pharma, or textiles).</li></ol><h4>Impact and Market Outlook</h4><ol><li><strong>Carbon Reduction:</strong> By reducing dependence on livestock and traditional agriculture, these technologies can significantly reduce emissions and water use.</li><li><strong>Market Growth:</strong> The global market for bioengineered biopharmaceuticals, consumables and biomaterials is expected to exceed $300 billion USD by the next decade.</li><li><strong>Policy-Driven Adoption:</strong> Adoption will accelerate with the rise of carbon taxes, consumer demand for sustainable products, and global biomanufacturing policies.</li></ol><h4>In sum…</h4><p>Investing in enabling technologies within the animal-free biopharmaceutical, consumables, and biomaterials sectors offers a unique opportunity to drive innovation, foster sustainability, and generate substantial returns. By focusing on companies that align with our investment criteria and targeting high-growth areas such as feedstock &amp; media development, cell line development, and bioprocess development, we can build a diversified portfolio that captures the upside potential of this rapidly evolving market.</p><p>This strategic approach not only positions us to capitalize on the growing demand for animal-free solutions but also allows us to play a pivotal role in shaping the future of the bioengineered systems ecosystem. Through thoughtful investment in enabling technologies, we can contribute to a more sustainable, efficient, and ethically aligned industry while achieving strong financial returns.</p><h4>Fund Overview</h4><ul><li>Fund Size: $100 million</li><li>Investment Focus: Early to mid-stage companies in bioengineered foods, materials, and chemicals, focusing on enabling technologies.</li></ul><h4>Capital Allocation Strategy</h4><ul><li>Initial Investments: 30–50% of the fund deployed in initial investments.</li><li>Focused on disruptive R&amp;D ventures with clear commercialization paths in bioengineering, process development and other synthetic biology applications.</li><li>Follow-on Investments: 50–70% of the fund is allocated to follow-on investments in existing portfolio companies.</li></ul><h3>🕵️ Case Study</h3><h4>Potential Portfolio Company</h4><p>Company Name<strong>: Scythe Bio</strong></p><p>Founders<strong>: 3</strong> (2 technical + 1 in business development)</p><p>Mission<strong>: </strong>Lower media costs coupled with microbial and mammalian strain engineering to reduce pharmaceutical drug prices and accelerate the development of bioengineered foods and biomaterials.</p><h4>Company Journey:</h4><ul><li>Two post-docs (bioinformatician + molecular biologist) developed proprietary platforms for animal-derived-component-free media optimization and microbial strain and mammalian cell line engineering.</li><li>Academic partnerships were established early on to test research concepts, resulting in peer-reviewed publications validating the core mechanism.</li></ul><p><strong>Funding &amp; Investment:</strong></p><ul><li>$600,000 USD, equally bootstrapped by all three co-founders.</li><li>Raised $100,000 in non-dilutive funding to further advance the technology readiness level (TRL) to stage 3 (proof-of-concept).</li><li>Received GMP certification to ensure quality control measures were in place pre-revenue.</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*6t3DKHfWwe2_lVCNS7zSUA.png" /><figcaption>Cap table analysis of Scythe Bio before external dilutive investments. Cells highlighted in yellow are values manually set by Scythe Bio.</figcaption></figure><p><strong>⤴️ Pre-Seed Stage</strong></p><p><strong>Investment: </strong>BowTie Venture Fund (or BowTie VC) invested $100,000 to scale the platform.</p><p><strong>Achievements:</strong></p><ul><li>Developed biochemical and genomics repositories for media and cell-line development.</li><li>Secured Freedom to Operate (FTO); patent application planned after the next funding round.</li><li>Signed partnerships with six entities (4 industry + 2 academic).</li><li>Generated <strong>$400,000 in revenue</strong> within the first year.</li></ul><p><strong>Additional Investment:</strong></p><ul><li><strong>BowTie VC:</strong> Contributed an additional $121,000, exercising <strong>10.9% pro-rata rights</strong>. Funds allocated for talent retention and patent application. <strong>1x liquidation preference exercised upon exit.</strong></li></ul><p><strong>⤴️ Seed Stage</strong></p><ul><li>Filed the patent application for their proprietary platform.</li><li>Expanded bench-scale operations by relocating out of an academic setting.</li><li>Acquired necessary safety certifications and hired additional lab personnel.</li><li>Signed two new clients while maintaining contracts with existing ones.</li><li><strong>BowTie VC:</strong> Maintains 10.9%, exercising <strong>10.9% pro-rata rights. 1x liquidation preference may be exercised upon exit.</strong></li></ul><p><strong>⤴️ Series A Milestones</strong></p><ul><li>Expanded business development team to 2 members and scientific team to 5.</li><li>Started development on <strong>Version 2</strong> of the platform, integrating <strong>digital twin technology</strong> for process development.</li><li>Revenue generated: 8M USD</li><li><strong>BowTie VC:</strong> Maintains 10.9%, exercising <strong>10.9% pro-rata rights. 1x liquidation preference may be exercised upon exit.</strong></li></ul><p><strong>⏭️ Series B Milestones</strong></p><ul><li>Established strategic collaboration with a <strong>bioprocessing partner</strong> to expand biomanufacturing capabilities.</li><li>Expanded client base into the European biopharma sector</li><li>Expected Revenue (FY 2024): 15M USD</li><li>Conservative projections: 13M USD</li></ul><h4>Cap Table Analysis</h4><p>Employee Stock Option Plan (ESOP) — 10% of company shares</p><p>Option to top up stock option pool to match 10% at every fundraising round</p><p><strong>Pre-seed round</strong>: raised 100k USD from BowTie VC</p><p><strong>Seed round</strong>: raised 121k USD from BowTie VC, maintaining an equity of 10.9%</p><p><strong>Series A round</strong>: raised 300k USD from BowTie VC, maintaining an equity of 10.9%</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*dFi71OO0Q-9eY_zzGv0nkg.png" /><figcaption>Funding rounds and their corresponding valuations for Scythe Bio. Provided by the author.</figcaption></figure><p>Series B ask: 4M at a pre-money valuation of 25M and post-money valuation of 33M.</p><p>👩🏽‍💻 Let’s calculate if investing in Scythe Bio over the next 3 years will be a viable investment.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*hciZ0NJXMykgSyKDCkXp5g.png" /><figcaption>Cap Table Analysis of total Investments made in Scythe Bio. Provided by the author.</figcaption></figure><h4>Scenario Analysis (Waterfall analysis)</h4><p>A waterfall analysis allows us to map out our return based on the price at which the company is sold upon exit.</p><p>The total investment made by BowTie VC from Pre-seed to Series B: 4,587,805 USD</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*_HaH48qiB1wz6upWkaK22Q.png" /><figcaption>Waterfall Analysis for BowTie Venture Fund. PS: Preferred shares with 1x Liquidation preference, CS: Common Shares</figcaption></figure><p><strong><em>Based on the Waterfall Analysis:</em></strong></p><p><strong><em>PS should be exercised if the company sale price is &lt;20M and</em></strong></p><p><strong><em>CS should be exercised if the company sale price is &gt;22M USD.</em></strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*hciZ0NJXMykgSyKDCkXp5g.png" /><figcaption>Series B Post-Money Cap Table displaying fully diluted ownership of BowTie VC. Provided by the author.</figcaption></figure><p><strong>Sensitivity Analysis (Exit Analysis)</strong></p><p>An exit analysis allows us to calculate the return on investment (ROI) based on the company’s annual revenue upon exit.</p><p>Company annual revenue projection at the end of Year 8 = 28M USD</p><p>Enterprise value/trailing twelve months (EV/TTM) ratio = at least 3.6x for biotech companies</p><p>Enterprise value after calculating debt (assuming 29%) = 71,316,000</p><p>BowTie Venture Fund’s fully diluted ownership over three stages of investment = 17.85%</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Pbls2004-MFBJ15zW9TM2Q.png" /></figure><p><strong>Worst Case Scenario</strong>: Considering that the company makes 50% of the projected revenue and is valued at a price four times its revenue (i.e 4x EV/Revenue), BowTie will make 1.5x of its total invested amount.</p><p><strong>Best Case Scenario</strong>: Considering that the company makes 100% of the projected revenue and is valued at 12x EV/Revenue, BowTie will make 9.2x of its invested amount.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*DhCIE8HoyVr34amGw0sorw.png" /><figcaption>If the company were to sell for 80M USD, BowTie Venture Fund would receive a return of &gt;19M USD, making it a 3.7x multiple on cash (MoC)</figcaption></figure><p>In summary, Scythe Bio stands out as a promising aggregator in the biomanufacturing industry. Its revenue growth from the Seed stage to its projected exit highlights its potential as a strong candidate for reinvestment in the Series B stage. Additionally, the company’s mission and future milestones align seamlessly with BowTie VC’s thesis, reinforcing our enthusiasm for this continued partnership.</p><p><em>This article was written by Dr Tarika Vijayaraghavan, founder and consultant at Trove Biosciences.</em></p><p><em>Please feel free to reach out in the comments section or at tarika@trovebiosciences.com should you have feedback for this article.</em></p><p>👋</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/1*YFPKuj7gysBIi-_8zgwnDA.png" /></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=89455ab71db6" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bioengineered-systems/investing-in-enabling-technologies-in-biotech-part-ii-89455ab71db6">Investing in Enabling Technologies in Biotech — Part II</a> was originally published in <a href="https://medium.com/bioengineered-systems">Bioengineered systems</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Investing in Enabling technologies in Biotech — part 1]]></title>
            <link>https://medium.com/bioengineered-systems/investing-in-enabling-technologies-in-biotech-part-1-7be97c0e0831?source=rss----8623283b878f---4</link>
            <guid isPermaLink="false">https://medium.com/p/7be97c0e0831</guid>
            <category><![CDATA[cellular-agriculture]]></category>
            <category><![CDATA[bioengineering]]></category>
            <category><![CDATA[alternative-protein]]></category>
            <category><![CDATA[bioeconomy]]></category>
            <category><![CDATA[investment-opportunities]]></category>
            <dc:creator><![CDATA[Tarika Vijayaraghavan, Ph.D. ]]></dc:creator>
            <pubDate>Mon, 18 Nov 2024 17:38:00 GMT</pubDate>
            <atom:updated>2025-05-09T15:11:58.857Z</atom:updated>
            <content:encoded><![CDATA[<h3>Investing in Enabling Technologies in Biotech — Part I</h3><p>The coming decade will see a rise in biomanufacturing. Here’s what you need to know about it —</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*kjiN2or9Qo541dlt" /><figcaption>Photo by <a href="https://unsplash.com/@yassine_khalfalli?utm_source=medium&amp;utm_medium=referral">Yassine Khalfalli</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><h4><strong>Rationale:</strong></h4><p>The term ‘bioeconomy’ is defined as <strong>“<em>the knowledge-based production and utilization of biological resources, innovative biological processes and principles to sustainably provide goods and services across all economic sectors”</em></strong> — <a href="https://www.sciencedirect.com/topics/engineering/bioeconomy"><em>Global Bioeconomy Summit</em></a>.</p><p>The US bioeconomy market alone currently stands at 1 trillion USD and is estimated to be <a href="https://www.forbes.com/sites/johncumbers/2022/09/12/white-house-inks-strategy-to-grow-trillion-dollar-us-bioeconomy/">30x </a>in the next two decades. With policy initiatives like the <a href="https://usda.gov/topics/biotechnology/bioeconomy#:~:text=The%20Biden-Harris%20Administration%20launched,resilience%2C%20and%20national%20and%20economic">U.S. National Biotechnology and Biomanufacturing Initiative</a>, <a href="https://bmi.dbtindia.gov.in/">India’s BioE3 policy</a> and <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC9995158/#:~:text=DEVELOPMENT%20GOALS%20OF%20CHINESE%20BIOECONOMY&amp;text=According%20to%20the%20plan%2C%20China,I%3A%20(2021%E2%80%932025)">China’s Bioeconomy Development Roadmap</a>, advancing biomanufacturing capacity, the global shift towards biomanufacturing in the areas of vaccine development, biobased foods and materials, biomining and bioremediation is gaining strong momentum.</p><p>Additionally, breakthroughs in synthetic biology — traditionally used in biopharmaceuticals — are increasingly <a href="https://www.nature.com/articles/s41467-020-20122-2">cross-pollinating</a> with biomaterials and food production sectors.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*L7rkhbp-ISXJ2du9qb2qrg.png" /><figcaption>Figure 1: Landscape overview of key aggregators in biobased solutions — a non-exhaustive list.</figcaption></figure><p>Thus, the convergence of bioengineering innovations across biopharmaceuticals, food, and materials opens vast market opportunities and paves the way for enabling technologies. Enabling technologies are key business aggregators of the bioeconomy sector, currently representing a market size of &gt;260 billion USD. Bioengineered agtech systems, such as microbial and precision-fermented high-value ingredients, enzymes and other chemicals, are promising alternatives, currently representing a <a href="https://www.futuremarketinsights.com/reports/genetically-modified-foods-market">100 billion USD</a> market size with steady growth.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*M-fAdxk0waQyWCCSL1_DmQ.png" /><figcaption>A) Bioeconomy in a nutshell B) Use cases of bioengineered systems C) Key updates announced in 2024 in the realm of biomanufacturing.</figcaption></figure><h4>Four Reasons to Invest in Enabling Technologies</h4><ul><li><strong>Early Revenue Generation:</strong> Enabling technologies often generate revenue faster than end-product companies. By providing essential tools, services, or platforms that other companies rely on, they can secure early-stage contracts, licenses, or partnerships, ensuring a faster return on investment.</li><li><strong>Scalability Potential:</strong> With the discovery of CRISPR/CAS9 technology in 2012, the last decade saw a <a href="https://www.bcg.com/capabilities/digital-technology-data/emerging-technologies/expert-insights/nicolas-goeldel">steady growth</a> in strain development, resulting in lowered costs in biomanufacturing. Segments within enabling technologies often serve as versatile platforms that can be adapted for multiple applications across different industries, including food, textiles, cosmetics, and pharmaceuticals, allowing for diversified revenue streams and scalability and reducing investment risks.</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/800/1*dhHgg2sR3PG4W10bLOv9Iw.png" /><figcaption>Analysis of M&amp;A exit in life sciences vs the global market. Source: <a href="https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-m-and-a-shows-new-signs-of-life">McKinsey &amp; Co</a></figcaption></figure><ul><li><strong>Higher Chances of Profitable Exit: </strong>Compared to the global M&amp;A market, the life sciences sector performed <a href="https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-m-and-a-shows-new-signs-of-life">significantly well</a> in deal counts for M&amp;As in 2023. Most deals in 2023 were made with smaller biotech companies (25–50M USD valuation) with a greater focus on acquiring <a href="https://www.mckinsey.com/capabilities/m-and-a/our-insights/life-sciences-m-and-a-shows-new-signs-of-life">biotech assets for easy R&amp;D integration</a>. Given their adaptability and central role in industry processes, enablers are more prone to getting acquired by industry incumbents.</li><li><strong>Driving Innovation and Efficiency:</strong> Accelerating research and development (R&amp;D) within one sector enables functionality in parallel sectors through innovation and data generation efficiency. By investing in niche-enabling technologies, investments can support the creation of more efficient, cost-effective, and scalable solutions, driving overall industry growth and profitability.</li></ul><h4>Key Focus Segments and Macrotrends</h4><p>Here is an outline of the most attractive segments for investment opportunities within the enabling technology sector:</p><p>1. <strong>Feedstock &amp; Media Development</strong> (Market Size: $23 Billion USD): This segment is critical for optimizing cell growth and productivity, making it an attractive area for investment. Innovations that develop cost-effective, sustainable feedstock and media solutions will significantly impact production efficiency, reducing costs and driving industry adoption.</p><p>🔎 <strong>Macro Trends: Wastewater recycling feedstock, non-serum-based cell culture media, animal and marine cell line and specific cell culture media, phytomining, forestry waste conversion, biohydrogen production</strong></p><p><strong>⚙️ Key Players: </strong><a href="https://hyfe.tech/"><strong>Hyfe</strong></a><strong>, </strong><a href="https://newformfoods.com/"><strong>Newform foods</strong></a><strong>, </strong><a href="https://fibenol.com/"><strong>Fibenol</strong></a></p><p>2. <strong>Cell Line Development</strong> (Market Size: $10 Billion USD): Developing robust and high-yield cell lines is essential for the scalability and commercial viability of animal-free products. Investing in companies that excel in this area will provide access to foundational technology with applications across multiple industries.</p><p>🔎 <strong>Macro Trends: AI-based technologies in strain and cell optimization, Cell line generation with high proliferation rates, high-throughput DNA library synthesis</strong></p><p><strong>⚙️ Key Players: </strong><a href="https://www.thecultivatedb.com/"><strong>Cultivated B</strong></a><strong>, </strong><a href="https://triplebar.com/"><strong>TripleBar</strong></a><strong>, </strong><a href="https://profuse-tech.com/"><strong>Profuse</strong></a><strong>, </strong><a href="https://www.opobio.com/"><strong>Opo Bio</strong></a><strong>, </strong>‍<a href="https://www.64xbio.com/"><strong>64xBio</strong></a></p><p>3. <strong>Bioprocess Development</strong> (Market Size: $30 Billion USD): As the largest market segment, bioprocess development offers tremendous investment potential. Efficient, scalable bioprocessing solutions are vital for the commercialization of animal-free products. Investments can support technologies that improve productivity, reduce operational costs, and accelerate time to market.</p><p>🔎 <strong>Macro Trends: optogenetics to for cell growth, plants as bioreactors, modular/micro bioreactors</strong></p><p><strong>⚙️ Key Players: </strong><a href="https://www.prolific-machines.com/"><strong>Prolific Machines</strong></a><strong>, </strong><a href="https://www.finally-foods.com/"><strong>Finally Foods</strong></a><strong>, </strong><a href="https://kyndatech.com/"><strong>Kynda</strong></a><strong>, </strong><a href="https://www.ark-biotech.com/"><strong>ARK Biotech</strong></a></p><p>Enabling technologies offer efficient, cost-effective and sustainable ways to speed innovation and growth in the global bioeconomy sector, thus making this sector ripe for strategic and capital investment opportunities.</p><p>Additionally, advancements in synthetic biology are benefiting industries like biopharmaceuticals, biomining, and chemicals, broadening the market potential for bioengineered products, now valued at over 300 billion USD. Enablers of bioengineering products present a lucrative and sustainable investment opportunity, contributing to an ethical, greener future and driving market growth.</p><p>In the next segment of this article, I will explore this investment thesis through the lens of a hypothetical VC company. The VC firm’s investment strategy will follow the global bioeconomy sector with a focus on emerging opportunities in food and biomaterial applications.</p><p><em>This article was written by Dr Tarika Vijayaraghavan, founder and consultant at Trove Biosciences.</em></p><p><em>Please feel free to reach out in the comments section or at tarika@trovebiosciences.com should you have any feedback.</em></p><p>👋</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7be97c0e0831" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bioengineered-systems/investing-in-enabling-technologies-in-biotech-part-1-7be97c0e0831">Investing in Enabling technologies in Biotech — part 1</a> was originally published in <a href="https://medium.com/bioengineered-systems">Bioengineered systems</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Supporting cells through scaffolds and their close cousins]]></title>
            <link>https://medium.com/bioengineered-systems/supporting-cells-through-scaffolds-and-their-close-cousins-f3b7473dd239?source=rss----8623283b878f---4</link>
            <guid isPermaLink="false">https://medium.com/p/f3b7473dd239</guid>
            <category><![CDATA[biomaterials]]></category>
            <category><![CDATA[cellular-agriculture]]></category>
            <category><![CDATA[scaffold]]></category>
            <category><![CDATA[alternative-protein]]></category>
            <category><![CDATA[microcarrier]]></category>
            <dc:creator><![CDATA[Tarika Vijayaraghavan, Ph.D. ]]></dc:creator>
            <pubDate>Tue, 12 Nov 2024 20:11:49 GMT</pubDate>
            <atom:updated>2024-03-11T16:05:20.774Z</atom:updated>
            <content:encoded><![CDATA[<p><em>It’s all about scaffolds! In this article, I discuss scaffolding materials and share studies using plant-based alternatives to develop cultivated foods. Don’t have the time to read this entire article? Scroll down to read the TL;DR version👇</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*5toFDtyKGOzgp5ZtHZ_reA.png" /><figcaption>Meat Platter, Canva</figcaption></figure><p>The future of cellular agriculture holds exciting promises, especially in cultivated meat and seafood production. Crafting meat from animal cells involves intricate systems working harmoniously to yield a textured product. One key player steps into the spotlight in this innovation journey: scaffolds.</p><p>Similar to how scaffolds support construction workers in building structures, biological scaffolds play a pivotal role in cellular agriculture. Inside the animal body (<em>in vivo conditions</em>), the area around cells, known as the extracellular matrix (ECM), provides support and access to nutrients. To mimic these conditions outside the animal body, we rely on materials such as scaffolds and their counterparts, like microcarriers and hydrogels. Thus these materials facilitate the growth of cells in high numbers in bioreactors, providing essential cues for differentiation and multiplication.</p><h4><strong>Qualities of an Ideal Biological Scaffold 🕸️</strong></h4><p>For cultivated meat applications, the perfect biological scaffold must possess specific characteristics:</p><ul><li>Biocompatibility: Ensuring no harm to cells.</li><li>Porosity: To add (or <em>seed</em>) cells, allow cell growth throughout the material and ensure nutrient transfer to individual cells.</li><li>Mechanical Strength: Holding cells together effectively.</li></ul><p>To be sustainable and scalable with sensory properties, an ideal scaffold should also be</p><ul><li>Free of animal ingredients</li><li>Cost-effective</li><li>Palatable and nutrient-rich</li></ul><h4>Plant-Based Scaffolds Take Center Stage 🎙️</h4><p>A recent study examined a blend of edible <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871916/">plant-based gel scaffolds</a> and protein additives, including gellan gum, agarose, xanthan-locust bean gum, soy protein, and pea protein. The findings were promising, with all three gel-protein blends proving biocompatible and credible candidates for cultivated meat production. Interestingly, gellan gum emerged as the most effective scaffold, followed closely by the agarose blend.</p><p>In other studies, edible <a href="https://pubmed.ncbi.nlm.nih.gov/35533444/">wheat protein</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/37120203/">pumpkin seeds</a> and <a href="https://pubmed.ncbi.nlm.nih.gov/37803690/#:~:text=Moreover,%20these%20microcarriers%20enabled%20cell,interact%20with%20cell%20surface%20receptors.">chickpea isolates</a> have offered promising solutions as plant-based alternatives for animal-based (<em>largely gelatin</em>) scaffolds and microcarriers.</p><p>Microcarriers are like scaffolds, offering a larger surface area for cells to attach and grow in large numbers (proliferate). However, unlike scaffolds, these can be detached from the cells or filtered out and do not offer structural support while forming the final meat product.</p><p>Researchers explored the application of wheat protein in crafting 3D scaffolds to support mouse and bovine cells. The study successfully developed porous wheat glutenin sponges, showcasing the potential of plant-based scaffolds in supporting cell proliferation and differentiation.</p><p>Another study looked at inexpensive cross-linked <a href="https://pubmed.ncbi.nlm.nih.gov/36916732/">soy protein fibrils</a> as scaffolding material which offered high porosity and stability and promoted mouse cell proliferation without the need for any additional cell-supporting molecules or coating.</p><p>As for microcarriers or ‘edible microbeads’, pumpkin seeds and chickpea protein isolates offer excellent solutions for cell attachment and proliferation. These microbeads have been tried on a plethora of mammalian cell types including mouse myoblast, mouse embryos, chicken and porcine muscle cells.</p><h4>Looking Forward →</h4><p>Scaffolding materials have been successfully utilized in therapeutic strategies for biological components since the 1980s. The cultivated meat industry takes a lot of its inspiration from fundamental research conducted to offer healthcare solutions. Here are some areas of innovation that may be a tremendous value addition to the cultivated food industry:</p><p><strong>Scaffold cost</strong>: Currently, media costs make up to <a href="https://gfi.org/resource/cultivated-meat-media-growth-factor-survey/#Executive-Summary">50% of the overall operating costs</a> of cultivated foods production. The cost of scaffold or cell support materials can significantly reduce the final cost of the product. Companies can innovate further by using <a href="https://www.frontiersin.org/articles/10.3389/frfst.2023.1208298/full">agricultural waste streams</a> as low-cost scaffolding materials, leveraging insights from this recently published study.</p><p><strong>Fungi as scaffolding material</strong>: The fungal root-like network called mycelia is considered a <a href="https://www.greenqueen.com.hk/mycelium-meat-8-of-the-best-brands-turning-fungi-root-into-whole-cut-steak-chicken-bacon-deli-meats/">low-cost, nutritious and scalable alternative</a> for developing meat analogs. However, their role as scaffolds has been explored only in <a href="https://pubmed.ncbi.nlm.nih.gov/35977409/">cultivated fat</a> applications thus far. Exploring this whitespace could offer solutions to the cultivated foods industry.</p><p><strong>Scaffold-free technology</strong>: While not all scaffolds can be <em>ideal</em>, it is possible not to incorporate scaffolding materials to support cells. In a scaffold-free scenario, cells can be engineered to secrete <a href="https://onlinelibrary.wiley.com/doi/full/10.1002/advs.202102908">their own ECM</a> which could prove advantageous from a sensory and regulatory point-of-view. Companies like <a href="https://www.caromeats.com/">Evolved Meats</a> (previously Caro Meats) and <a href="https://www.ohayovalley.com/">Ohayo Valley</a> are looking at developing whole-cut meats using scaffold-free technology.</p><h4>TL;DR👩🏽‍💻</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/734/1*6sq-Ta9Yx6_tDtNt_IjxKw.png" /></figure><p>📌 Cellular agriculture is where cells are cultured in growth media and other nutrients to produce traditional animal-based ingredients.</p><p>📌 In addition to growth media, cells require supporting proteins to thrive (microcarriers) and give them structural integrity (scaffolds).</p><p>📌 An ideal scaffold should be mechanically strong, offer porosity and nutrient access to the cells, and be scalable, cost-effective, tasty, and nutritious.</p><p>📌 Researchers utilized wheat protein to create 3D scaffolds supporting cell growth and differentiation.</p><p>📌 Plant-based scaffolds such as gellan gum and agarose blend have effectively offered structural support to animal cells.</p><p>📌 Wheat and soy protein isolates as scaffolds offer cost-effective and scalable solutions.</p><p>📌 Edible microbeads (microcarriers) coated with chickpea protein and pumpkin seeds have resulted in high cell attachment and growth rate, indicating a significant potential for animal-free media components for cultivated foods.</p><p>📌 Future solutions could work towards reducing scaffold costs, exploring fungal alternatives, and aiming for scaffold-free technologies.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/1*YFPKuj7gysBIi-_8zgwnDA.png" /></figure><p><em>✨Reach out to me at tarika@trovebiosciences.com to discuss your altprotein needs!</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f3b7473dd239" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bioengineered-systems/supporting-cells-through-scaffolds-and-their-close-cousins-f3b7473dd239">Supporting cells through scaffolds and their close cousins</a> was originally published in <a href="https://medium.com/bioengineered-systems">Bioengineered systems</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[5 Takeaways from the science of cultivated meat research (in 2024)]]></title>
            <link>https://medium.com/bioengineered-systems/5-takeaways-from-the-science-of-cultivated-meat-research-from-2024-papers-456b3259339d?source=rss----8623283b878f---4</link>
            <guid isPermaLink="false">https://medium.com/p/456b3259339d</guid>
            <category><![CDATA[cellular-agriculture]]></category>
            <category><![CDATA[food-technology]]></category>
            <category><![CDATA[cultivated-meat]]></category>
            <category><![CDATA[alternative-protein]]></category>
            <dc:creator><![CDATA[Tarika Vijayaraghavan, Ph.D. ]]></dc:creator>
            <pubDate>Tue, 12 Nov 2024 20:11:40 GMT</pubDate>
            <atom:updated>2024-05-16T14:02:56.126Z</atom:updated>
            <content:encoded><![CDATA[<p>A recap: Cultivated meat is the slaughter-free version of conventional meat, where meat is made from cells grown in suitable media (vitamins, minerals, proteins, etc.) and conditions (temperature, pH, oxygen, etc.).</p><p>The concept of cultivated meat was proposed as early as 1880 in a science-fiction novel called <em>Mizora </em>as a way of producing food without the presence of domesticated animals. Over time, bright minds came together and turned the sci-fi concept into today’s reality. Companies like Upside Foods, GOOD Meat, Aleph Farms, SuperMeat and Vow have achieved regulatory approvals from the US, Israel and Singapore governments to produce and sell their innovations!</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/750/1*hWaklf3df6fQSr0KbOgNyg.jpeg" /><figcaption>Cultivated Japanese quail meat ‘Qualia’ debuted by Vow in April 2024</figcaption></figure><p>The evolving academic landscape of the cultivated meat industry mirrors its rapid growth, marking a stark contrast from its position even a decade ago. Over the past months, I have closely monitored academic research and review papers from January to May 2024 to gain deeper insights into its dynamic landscape.</p><p>Let’s dive in -</p><h4><strong>1. Publication focus</strong>:</h4><p>Out of 58 papers published this year in cultivated meat research, over 45 (~75%) were technology-related. The term ‘technology’ encompasses all research and review publications highlighting operations from cell line sourcing to end-product development in cultivated meat. Around 15% of publications focused on consumer perception, showcasing the most geographical diversity in terms of author and university data. As the field progresses, research around the marketing, communications and labelling of cultivated meat products will play a crucial role in raising awareness and helping understand consumer behaviour.</p><h4>2. <strong>Geographical distribution:</strong></h4><p>Of the 45, 13 papers were published by South Korea and 12 by China, together comprising over 50% of technical papers published, displaying a similar trend compared to <a href="https://twitter.com/elliotswartz/status/1750162761617686768">2023</a>. In 2016, China published <a href="https://www.theguardian.com/world/2016/jun/20/chinas-meat-consumption-climate-change">guidelines</a> to cut its annual meat consumption by half to meet its carbon emission goals by 2030. Considering that the Chinese alternative protein market is valued at over <a href="https://time.com/5930095/china-plant-based-meat/">$900 million</a> and the government is <a href="https://www.reuters.com/business/chinas-cellx-pilots-lab-grown-meat-production-eyes-us-market-2023-08-10/#:~:text=The%20firm%20opened%20a%20pilot,tonnes%20of%20meat%20a%20year.">offering incentives</a> to cultivated meat companies, it is highly likely that academic research will receive substantial funding to help meet sustainability goals.</p><p>China’s top tech research categories include <strong><em>scaffolds and cell media formulation.</em></strong></p><figure><img alt="A comparative chart displaying the total no of publications in top 5 countries between 2023 and H1 2024 (Data accumulated before 7 May 2024)" src="https://cdn-images-1.medium.com/max/1024/1*2M0Fdh23-VzVaRwT8yxp8Q.png" /><figcaption>Comparative analysis of publications in the top 5 countries — 2023 vs H1 2024</figcaption></figure><p>Earlier this month, South Korea announced its <a href="https://www.foodingredientsfirst.com/news/south-korea-stimulates-cultivated-meat-growth-with-regulation-free-special-zone.html#:~:text=South%20Korea%20is%20a%20global,engineering%2C%20cell%20biology%20and%20biomaterials.">regulation-free special zone</a> housing 10 South Korean cultivated companies to innovate their products. This significant milestone aims to accelerate research and innovation over the next 5 years.</p><p>Korea’s top tech research categories include <strong><em>cell proliferation, cell media formulation and biofabrication.</em></strong></p><h4>3. <strong>Scaffolds: some newer, some stronger ones emerge</strong></h4><p>Scaffold proteins in cultivated meat processing help grow, support and shape cellular biomass to create the desired whole meat cut structure. A deeper dive into scaffolds can be found in my <a href="https://medium.com/@tarika_13698/supporting-cells-through-scaffolds-and-their-close-cousins-f3b7473dd239">previous article</a>. This year’s research has focused on low-cost, scalable, edible scaffolds that offer significant value to the overall production cost and sensory properties of cultivated meat. For example,</p><p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11063153/">Mycelium</a>: The globally used fungi <em>A. oryzae </em>significantly aided in the differentiation (specialization into muscle cells) and proliferation (growth) of bovine satellite cells. The concept of using a supportive component like mycelia in a single flask/bioreactor with cellular biomass has the potential to substantially lower cost and improve unit economics.</p><p>Nanofibers: Researchers utilized cellulose acetate nanofibers (CAN) as scaffolds <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10796801/">to induce</a> and enhance the differentiation of chicken muscle satellite cells directly in the cell growth medium. The CAN scaffolds are particularly valuable because they can be added to the same growth medium right from the beginning without requiring a specialized medium for scaffolding alone, thereby offering a cost-effective solution for cultivated meat production.</p><p>Probiotic bacteria: This <a href="https://pubmed.ncbi.nlm.nih.gov/37805297/">opinion piece</a> suggests a framework that involves co-culturing probiotic bacteria (eg lactic acid bacteria) with molecules that result in edible polymers that have the potential to act as scaffolds to support mammalian tissue culture.</p><h4>4. <strong>The evolving nature of cell media formulation</strong></h4><p>A commonly used process for cultivated meat involves acquiring satellite (or starter) cells from an animal of choice, growing the cells in growth media so they proliferate (multiply in number) and then differentiate (specialization into muscle cells). Simply put, cell culture media is a nutrient-rich broth of cell-supporting molecules like sugars, amino acids, vitamins, salts, growth factors, etc., that can help create a biomass of healthy and viable cells. Go ahead and read <a href="https://gfi.org/science/the-science-of-cultivated-meat/deep-dive-cultivated-meat-cell-culture-media/">this deep dive</a> by The Good Food Institute to learn more about cell culture media components.</p><p>The industry is actively trying to pivot from a serum-based (specifically fetal bovine serum, or FBS) formulation that has been traditionally used for cell culture purposes. Here are a few studies that offer FBS-free solutions:</p><p>Recombinant fibroblast growth factor (FGF1): FGF1 is <a href="https://pubmed.ncbi.nlm.nih.gov/35681108/">widely known</a> for its role in cell proliferation and differentiation. <a href="https://pubmed.ncbi.nlm.nih.gov/38129067/">This 2024 study</a> discovered that in the presence of recombinant (created in a lab) bovine FGF1, myoblast (muscle precursor) cells can proliferate without requiring any serum, thereby aiming to reduce the overall cost of culture media.</p><p>Marine algae: <em>Chlorococcum littorale</em> is a marine microalgae that is known for its high lipid content. In the context of cultivated meat, <a href="https://pubmed.ncbi.nlm.nih.gov/37904720/">researchers</a> extracted growth factors from <em>C. littorale</em> tested for mammalian cell growth and viability. Surprisingly, all cell lines displayed high proliferation rate in a serum-free environment.</p><p>Egg white: While not a serum replacement, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10904906/">this preliminary study</a>, which extracted ovalbumin from fertilized egg whites, shows promise in eliminating FBS usage by 50%.</p><h4><strong>5. Biofabrication: an emerging category?</strong></h4><p>While most papers largely focused on upstream developments (cell line optimization, cell media development, and scaffolding proteins), there is a significant trend toward understanding the fabrication or assembly of cellular aggregates for end-product formulation.</p><p>Current biofabrication techniques deployed in biomedical and cultivated meat studies utilize robotic assemblies to either structure cellular aggregates called ‘bioinks’ (bioprinting) or stack cell composite matrix that provide adhesion for cell growth (bioassembly).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/664/1*dQXRq9eWcZm3aeL-74uVAw.jpeg" /><figcaption>Cultivated meat using Biofabrication methods. Source: Albrecht et al., 2024</figcaption></figure><p><a href="https://onlinelibrary.wiley.com/doi/10.1002/adhm.202304058">This review</a> argues that bioprinting is a better technology for cultivated meat, especially when considering scaling up production. Bioprinting of muscle cells has resulted in better cell viability, fibre formation, alignment, and overall structure.</p><p>Key considerations for ‘bioinks’ include materials that are animal-free, edible, allergen-free, and cost-effective, among other things. Plant-based dietary carbohydrates like agarose, cellulose, pectins, and gums are suggested as cell adhesion materials.</p><h4>Lastly, a few wins for the cultivated meat industry</h4><p>Despite the current macroeconomic conditions i.e. a <a href="https://gfi.org/resource/cultivated-meat-and-seafood-state-of-the-industry-report/#:~:text=Cultivated%20meat%20and%20seafood%20companies%20raised%20%24225.9%20million%20globally%20in,emissions%20and%20address%20climate%20goals.">42% year-on-year drop</a> in investments in the cultivated meat sector, the industry has shown remarkable resilience.</p><p>On one hand, <a href="https://www.foodnavigator.com/Article/2024/02/22/Italy-s-cultivated-meat-ban-postponed#">Italy</a>, <a href="https://www.greenqueen.com.hk/france-cultivated-meat-lab-grown-ban-italy/">France</a>, and some states in the US received significant backlash regarding policy acceptance (I am looking at you, <a href="https://www.azcentral.com/story/money/food/2024/05/05/florida-lab-grown-meat-ban/73569976007/">Florida, Alabama, Arizona and Tennessee</a> 💔), while on the other hand, <a href="https://www.greenqueen.com.hk/cultured-lab-grown-meat-regulation-uk-israel-australia-us-eu-approval/">Switzerland, the UK, Australia, New Zealand</a>, <a href="https://www.betterbioeconomy.com/p/amazon-for-proteins-south-koreas">South Korea</a>, and <a href="https://www.greenqueen.com.hk/india-cultivated-meat-lab-grown-seafood-regulatory-framework/#:~:text=Additionally%2C%20research%20conducted%20by%20GFI,49%2C420%20jobs%20by%202030%20too.">India</a> have opened their doors to cultivated meat research and innovation.</p><p>Meatable recently announced that it can produce its cultivated sausage in just <a href="https://www.greenqueen.com.hk/meatable-production-cultivated-meat-lab-grown-pork-singapore/">4 days</a>, making it ~80% faster than other cultivated meat and 3000% faster than conventional animal agriculture methods.</p><p>Hybrid/blended meat has made its way to consumer retail shelves! GOOD Meat recently announced that it will sell its product, Good Meat 3, at Singapore’s Huber’s Butchery starting 16th May 2024. Good Meat 3 contains 3% cultivated chicken meat along with plant-based formulations. Exciting times, indeed!</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*09-Qqdtw5O8c9cNA0iSMYw.jpeg" /><figcaption>“Packages of GOOD Meat 3 displayed below, right below the Quail Bones” — Josh Tetrick, CEO, GOOD Meat. Source: X (Formerly known as Twitter)</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/1*YFPKuj7gysBIi-_8zgwnDA.png" /></figure><p>Did you find this mini-deep dive insightful? Do you have any feedback for me? Reach out on <a href="https://www.linkedin.com/in/tarikavr/">LinkedIn</a> or my email, tarika@trovebiosciences.com, if you’d like to connect!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=456b3259339d" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bioengineered-systems/5-takeaways-from-the-science-of-cultivated-meat-research-from-2024-papers-456b3259339d">5 Takeaways from the science of cultivated meat research (in 2024)</a> was originally published in <a href="https://medium.com/bioengineered-systems">Bioengineered systems</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Designing microbial strains for commercial production?]]></title>
            <link>https://medium.com/bioengineered-systems/designing-microbial-strains-for-commercial-production-332d459ef9ce?source=rss----8623283b878f---4</link>
            <guid isPermaLink="false">https://medium.com/p/332d459ef9ce</guid>
            <dc:creator><![CDATA[Tarika Vijayaraghavan, Ph.D. ]]></dc:creator>
            <pubDate>Tue, 12 Nov 2024 20:11:28 GMT</pubDate>
            <atom:updated>2024-08-12T23:01:12.811Z</atom:updated>
            <content:encoded><![CDATA[<h3>Here are 3 key strategies to enhance product titer, yield and overall productivity in cell factories</h3><p>📍<em>Don’t have the time to read the entire article? Scroll to the bottom to read the TL;DR version!</em></p><p>Since the advent of synthetic biology, microbial fermentation technology has soared from a lab-scale concept in universities to a <a href="https://www.precedenceresearch.com/microbial-fermentation-technology-market">USD 34 billion</a> market in 2024, with projections to capture a <a href="https://www.precedenceresearch.com/microbial-fermentation-technology-market">USD 60 billion</a> market in 2033.</p><p>The first step in strategizing the research and development foundation for microbial fermentation technology requires understanding strain biology, engineering, and optimization techniques while also considering the feasibility of scaling the process to commercial production.</p><p>This article discusses the different frameworks and strategies employed by CMOs and academic institutions as best-strain engineering practices, providing case studies and context for each.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XI4q4sgIoMSBSqzGtvtN_Q.png" /><figcaption>Steps involved in microbial fermentation. The dotted rectangle represents the steps involved in strain engineering and optimization. Image designed in Canva.</figcaption></figure><h4>Strain selection and engineering is older than you think</h4><p>Strain biology for microbial fermentation involves surveying a number of microorganisms that can be leveraged to create high-value, high-quality products that are otherwise difficult to extract in their natural form.</p><p>For example, synthetic biology techniques made the commercial production of insulin as a diabetes medication possible. The genetic code or blueprint for insulin was introduced into <em>E. </em><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203937/"><em>coli</em> or <em>S. cerevisiae</em></a> (baker’s yeast) and made to ferment over a few days before extracting the protein from the cells. In the early 1920s, insulin was extracted from <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205949/">canine</a> and <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528409/">porcine</a> pancreas, which was both inefficient and cumbersome. Today, all commercially produced insulin is <a href="https://www.acs.org/education/whatischemistry/landmarks/insulin.html">genetically engineered</a>.</p><p>Strain engineering is the first and one of the most important aspects to consider when working towards generating an end product of interest. Strain selection and feedstock have a direct effect on -</p><p>Titer: Concentration of protein (or product) of interest in the overall medium.</p><p>Yield: The ratio of the amount of end product formed as an output to the amount of feedstock as an input.</p><p>Productivity: The amount of end product produced in unit weight per unit of time.</p><p>Cost: the $$ amount taken to produce a unit value of the end product of interest.</p><p><strong><em>The Framework: </em></strong><a href="https://pubmed.ncbi.nlm.nih.gov/37656881/">Abbate et al.</a> discuss the Design-Build-Test-Learn (DBTL) framework to optimize strain engineering to ensure scalability up to commercial scale levels. This iterative framework involves assessing strain strength until the desired performance is achieved.</p><p><strong>Design:</strong> Consider Adaptive Laboratory Evolution (ALE), deep sequencing and in silico strategies to train ML algorithms using existing biochemical pathways and omics data sets: <a href="https://www.nature.com/articles/s41467-018-03232-w.pdf">Rugbjerg 2018</a>, <a href="https://link.springer.com/content/pdf/10.1186/s12934-023-02144-9.pdf">Liu, 2023</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/37656881/">Abbate, 2023</a>.<br><strong>Build:</strong> Utilize CREATE, which is a CRISPR-based tool that can introduce different mutations in parallel to asses strain quality when tested. This methodology also involves molecular barcodes in the base plasmid for strain identification purposes. The Design and Build stages assess genetic manipulations of strains for better productivity. <br><strong>Test:</strong> Experimentally evaluate in parallel bioreactor systems to assess the phenotype and genotype of the desired criteria. <br><strong>Learn: </strong>Analyze data gathered from the ‘test’ phase to gain insights into the strains’ behaviour and performance.</p><h3>Strain Design and Optimization Strategies</h3><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*y5v6ZpJKJND0YDmt1AuxNw.png" /><figcaption>Strain Engineering as a method of optimizing for titer, yield, productivity and cost</figcaption></figure><h4>1. Guided engineering approaches (<a href="https://link.springer.com/article/10.1007/s44307-024-00018-8">Xu, 2024</a>)</h4><p>Experimental approaches such as transcription factor (TF) engineering, membrane/transporter engineering, stress protein engineering, and ALE are among the most utilized and proven approaches to ensuring high titer and productivity during scale-up.</p><p><strong><em>Transcription factor engineering</em></strong></p><p>TFs are proteins that enhance or suppress genes, thereby increasing or decreasing their respective protein production. Some TFs can regulate a wide-variety of genes, known as global TFs, while some regulate specific genes called specific TFs. Knowing which gene locus to engineer to drive the growth of the protein of interest is key. For example, In <em>S. cerevisiae</em>, the <a href="https://pubmed.ncbi.nlm.nih.gov/7002731/">COUP</a> transcription factor promotes the production of ovalbumin, whereas the<a href="https://pubmed.ncbi.nlm.nih.gov/19718678/"> AOX promoter</a> in <em>P. pastoris</em> was shown to drive titers as high as 5g/L of the same protein. In <em>T. reesei</em>, the transcription factor <a href="https://pubmed.ncbi.nlm.nih.gov/38671155/">STE12</a> is largely attributed to carbon source utilization and biosynthesis of secondary metabolites, which in turn helps with productivity and drives gene expression.</p><p><strong><em>Membrane/transporter protein engineering</em></strong></p><p>Secondly, the lipid bilayer plasma membrane of the microbial host cells plays a crucial role in nutrient exchange and metabolite transport, and is an important regulator of osmotic pressure. Efficient optimization of cell membrane lipids through membrane engineering can significantly improve productivity and tolerance. For example, in <em>S. cerevisiae</em>, <a href="https://link.springer.com/article/10.1007/s44307-024-00018-8">researchers</a> observed that increasing oleic acid content in the cell membrane required higher ethanol concentration in the media. To enhance yeast strains’ tolerance to ethanol, they overexpressed a rat elonginase gene in the yeast cells. This modification not only conferred resistance to ethanol, n-butanol and n-propanol but also dramatically increased oleic acid content in the cell membrane.</p><p><strong><em>Stress protein engineering</em></strong></p><p>Microbial strains are often subjected to stresses at commercial scales that can negatively impact cellular growth and health. Optimizing stress response is another crucial element in strain engineering to produce high-titer recombinant proteins. For example, high titers of industrially relevant antibodies VHH and scFv was achieved by <a href="https://www.sciencedirect.com/science/article/pii/S1871678423000018">overexpressing</a> a stress response transcription factor <em>MSN4</em> and three chaperone proteins (proteins that help fold other proteins) — <em>KAR2, LHS1, ERJ5</em>. This resulted in a 2-fold increase in antibody production in fed-batch cultivations.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*Rdq4tXK8Oq_OCU7GCxY1eQ.jpeg" /><figcaption>Strain engineering and optimization approaches. Source: <a href="https://link.springer.com/article/10.1007/s44307-024-00018-8">Xu, 2024</a></figcaption></figure><h4>2. The OptDesign strategy (<a href="https://pubs.acs.org/doi/pdf/10.1021/acssynbio.1c00610">Jiang, 2022</a>):</h4><p>Computational modelling of metabolic pathways can deliver significant insights into optimal biochemical production. The OptDesign is one such computational strategy that involves a two-part process that identifies changes in metabolic activity between wild-type and mutated strains. Then, it determines the minimal genetic changes needed for efficient production of metabolites.<br><strong><em>Case study: </em></strong>At over <a href="https://www.sciencedirect.com/science/article/abs/pii/B9780444636621000270">USD 7.2 billion</a> market cap, succinic acid is used as a flavouring agent and in pharmaceutical and cosmetic applications. Commercial production of succinate (a form of succinic acid in living organisms) is carried out in <em>E. coli </em>and<em> S. cerevisiae</em>. By utilizing studies in the literature and metabolic pathway databases, OptDesign identified key genes that can be knocked out, knocked down or upregulated in the succinate biosynthesis pathway to yield a high amount of succinate. OptDesign suggested a total of 8 manipulations which included 5 knockouts, 2 upregulations and 1 knockdown. This tool works for both endogenous (produced within the organism) and heterologous (genetic code introduced from another organism) proteins<br>Strain: <em>E. coli</em><br>Feedstock: glucose<br>Note: OptDesign is the most advanced tool compared to the conventionally used OptKnock, OptForce OptRAM, and NIHBA, among others. Access OptDesign on Github <a href="https://github.com/Chang88ye/OptDesign"><em>here</em></a><em>.</em></p><h4>3. The DySScO strategy: (<a href="https://bmcbiotechnol.biomedcentral.com/articles/10.1186/1472-6750-13-8">Zhuang, 2013</a>)</h4><p>Researchers at the University of Toronto suggest that metabolic engineering and bioprocess engineering need to go in tandem to correctly assess product yield, titer, productivity and cost. The dilemma of metabolic models is that there is often a trade off between product yield and the microbial cell growth rate — leading to either low yield and greater biomass or vice versa. By utilizing dynamic flux balance analysis (dFBA) that can predict yield and productivity using metabolic models, scientists invented the Dynamic Strain Scanning Optimization strategy (DySScO) strategy focuses on designing strains that can optimized for titer, yield, productivity and cost. Simply put, the DySSCo strategy is comprised of three phases — scanning, design and selection:</p><p>Scan: Explore opportunities for product yield and growth rate at fixed biomass uptake levels. Then, create in silico strains keeping the product yield fixed and simulate how these strains would perform in a fed-batch or batch culture mode using dFBA. Assess individual strain scores based on the consolidated strain performance (CSP) using titer, yield and productivity as key metrics.</p><p>Design: Identify the strain with the best performance for microbial cell growth rate. Using strain design algorithms (Genetic Design through Local Design Search; GDLS), test the feasibility of high-yield strains optimized for product yield.</p><p>Select: Simulate the condition for batch and fed-batch culture mode using dFBA. Assess how these newly designed strains perform using CSP and select the strain with the highest CSP score.</p><p><strong><em>Case study:<br></em></strong>Producing the commodity chemical succinate in <em>E. coli</em> strain using the DySScO strategy, involved creating 10 hypothetical flux distributions during the scanning phase. By optimizing for maximum succinate yield, growth and productivity were determined. Next, using dFBA, these distributions were simulated in batch reactors. Strains with CSP that favoured yield, growth and productivity were considered. In the design phase, <em>E. coli</em> knock-out strains were generated using GDLS to link succinate production to the bacterial growth rate. Three strains were chosen out of this phase (YZ1, YZ2, YZ3). In the selection phase, these three strains were tested against yield, productivity and titer. Of the three, the YZ1 strain performed the best.</p><h3>TL;DR</h3><ol><li>Microbial production of heterologous proteins and lipids is a lucrative market that is gaining traction year after year.</li><li>Effective R&amp;D strategies for strain design and optimization require a blend of knowledge-based guided engineering and computational algorithmic approaches.</li><li>Guided engineering approaches involve genetic manipulation of transcription factors, membrane/transporters, and stress proteins to confer tolerance and improve yield.</li><li>Computational approaches like OptDesign and DySScO strategies involve combining metabolic models to enhance the overall strain performance. In OptDesign, genetic changes are identified to enhance metabolite production. The DySScO strategy combined metabolic and process engineering and dynamic flux balance analysis to optimize for yield, productivity and titer, simultaneously</li></ol><p><em>Did you find this mini-deep dive insightful? Do you have any feedback for me? If so, reach out on </em><a href="https://www.linkedin.com/in/tarikavr/"><em>LinkedIn</em></a><em> or my email, tarika@trovebiosciences.com.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/1*YFPKuj7gysBIi-_8zgwnDA.png" /><figcaption>🌻</figcaption></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=332d459ef9ce" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bioengineered-systems/designing-microbial-strains-for-commercial-production-332d459ef9ce">Designing microbial strains for commercial production?</a> was originally published in <a href="https://medium.com/bioengineered-systems">Bioengineered systems</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[3 ways to enhance protein expression using precision fermentation]]></title>
            <link>https://medium.com/bioengineered-systems/3-ways-to-enhance-protein-expression-using-precision-fermentation-f85b6fae27b5?source=rss----8623283b878f---4</link>
            <guid isPermaLink="false">https://medium.com/p/f85b6fae27b5</guid>
            <category><![CDATA[alternative-protein]]></category>
            <category><![CDATA[yeast]]></category>
            <category><![CDATA[synthetic-biology]]></category>
            <category><![CDATA[precision-fermentation]]></category>
            <category><![CDATA[cellular-agriculture]]></category>
            <dc:creator><![CDATA[Tarika Vijayaraghavan, Ph.D. ]]></dc:creator>
            <pubDate>Tue, 12 Nov 2024 20:11:18 GMT</pubDate>
            <atom:updated>2024-10-01T17:08:24.521Z</atom:updated>
            <content:encoded><![CDATA[<p>Think upstream!</p><h3>Researchers suggest three levers to adjust to maximize the production of yeast biomass and secreted proteins when using Pichia pastoris</h3><p>The landscape of food technology is slowly shifting towards better production methods to meet future sustainability demands. As an alternative to animal-based agriculture methods, microbial fermentation, more specifically, precision fermentation, is utilized to grow end products like <a href="https://www.greenqueen.com.hk/environment-sustainable-precision-fermentation-life-cycle-assessment-lca-scientific-research/">milk proteins</a>, <a href="https://every.com/do#:~:text=2.-,PRECISION%20FERMENTATION,converted%20into%20protein%20through%20fermentation.">egg protein</a>, <a href="https://agfundernews.com/designer-fats-in-focus-does-it-make-commercial-sense-to-produce-fats-via-precision-fermentation">fats</a>, <a href="https://www.ft.com/content/cfe2070f-c8f2-4145-9944-b72d6c7fa8ae">palm oil</a>, <a href="https://oobli.com/blogs/news/how-are-sweet-proteins-made#:~:text=It&#39;s%20a%20process%20akin%20to,with%20a%20nutrient%2Drich%20broth.">sweet proteins</a>, <a href="https://www.fastcompany.com/90848621/this-new-coffee-is-brewed-without-any-beans-but-all-the-caffeine-dont-worry">coffee</a> and <a href="https://planet-a-foods.com/">chocolate</a>, to name a few.</p><p>Microbial strains like<em> P. pastoris (also known as Komagataella phaffii), S. cerevisiae, Trichoderma reesei, </em>and<em> E. coli </em>are widely utilized in the industry to produce food ingredients. <em>P. pastoris</em> is the primary strain responsible for the meaty flavour (thank you, soy leghemoglobin) consumers like in an Impossible burger.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/750/1*PnWPHrPccOfZR4bNWLvWjg.jpeg" /><figcaption>Classic Grilled Burger. Courtesy <a href="https://impossiblefoods.com/recipes/classic-grilled-burger">Impossible Foods</a></figcaption></figure><h4>1. Strain:</h4><p>Researchers studied commercially available <em>P. pastoris</em> wild type strains NRRL Y-11430, NRRL Y-7556 and X-33 to understand optimal conditions for increasing heterologous protein (<em>genetic blueprint derived from an external source</em>) expression.</p><p>Compared to X-33, Y-11430 and Y-7556 exhibited rapid growth, with Y-7556 reaching biomass levels of 244 g of dry cell weight (DCW) per litre of media within 50 hours at a larger scale — one of the highest concentrations recorded for a wild type strain.</p><p>While a rapidly growing strain, Y-7556 faced some challenges with respect to cloning the heterologous protein of interest — mCherry 🍒</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/281/1*6f4WFiowjZpCS7wNlo7P6A.png" /><figcaption>Secreted mCherry protein in the media after x hours of fermentation (hours displayed above). Courtesy: <a href="https://pubmed.ncbi.nlm.nih.gov/39328387/">Shemesh and Fishman, 2024</a></figcaption></figure><p>Check out <a href="https://medium.com/@tarikavr/designing-microbial-strains-for-commercial-production-332d459ef9ce">this article</a> to learn more about strain optimization for precision fermentation 🫧</p><h4>2. Ploidy level:</h4><p>Using genetic methods, <em>P. pastoris </em>can exist as both haploid (1 set of chromosome) and diploid (2 sets of chromosomes).</p><p>Diploid versions of X-33 and Y-11430 (X-33_MAT1 and Y-11430_MAT7, respectively) displayed better carbon uptake ability and protein expression across different processing methods.</p><p>Y-11430 (diploid) showed significantly higher levels of protein expression compared to X-33 (diploid), indicating better strain efficiency over 120 hours of fed-batch fermentation — 5.5 g/L vs 1.7 g/L</p><figure><img alt="Bar graph displaying protein expression at various intervals of the fermentation cycle" src="https://cdn-images-1.medium.com/max/638/1*gWkiEqjBKwzcff4zQgE-GA.png" /><figcaption>The yellow bar indicates protein levels from X-33 (c) and Y-11430 (d). Courtesy: <a href="https://pubmed.ncbi.nlm.nih.gov/39328387/">Shemesh and Fishman, 2024</a></figcaption></figure><h4>3. Carbon source:</h4><p>Glucose, glycerol and dextrose were used as sugar sources to feed yeast growth. Typically <em>P. pastoris</em> feeds on methanol as the only carbon source, however, this paper also utilized other sources to determine yeast growth and carbon uptake rates.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/371/1*bP_nT5N9LN7OFItLv_PT9A.png" /><figcaption>Y-7556 (blue squares) performs best among the three within 50 hours of the fed-batch fermentation run. Courtesy: <a href="https://pubmed.ncbi.nlm.nih.gov/39328387/">Shemesh and Fishman, 2024</a></figcaption></figure><p>In shake flask experiments (250 mL), all three strains grew well on glycerol compared to glucose. In fed-batch 3.7 L fermenters, a similar trend was observed, with strains growing significantly more on glycerol compared to dextrose.</p><p>Thus, glycerol emerged as the efficient carbon source with a 40% increase in biomass concentration compared to glucose.</p><p>Additional notes to consider: this <a href="https://pubmed.ncbi.nlm.nih.gov/39328387/">study</a> was funded by an alternative protein think tank called the <a href="https://gfi.org/about/?gad_source=1&amp;gclid=Cj0KCQjwmOm3BhC8ARIsAOSbapWIuaUJ3bBsMFMamOamZ1w22pjb37aG_XFxnz2YWUymGMFeRLrIagYaAlsoEALw_wcB">Good Food Insitute</a> and the <a href="https://www.gov.il/en/departments/ministry_of_science_and_technology/govil-landing-page">Israel Ministry of Innovation, Science, and Technology.</a></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/1*YFPKuj7gysBIi-_8zgwnDA.png" /></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f85b6fae27b5" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bioengineered-systems/3-ways-to-enhance-protein-expression-using-precision-fermentation-f85b6fae27b5">3 ways to enhance protein expression using precision fermentation</a> was originally published in <a href="https://medium.com/bioengineered-systems">Bioengineered systems</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[50+ companies are brewing the future of food]]></title>
            <link>https://medium.com/bioengineered-systems/50-companies-are-brewing-the-future-of-food-055defda3643?source=rss----8623283b878f---4</link>
            <guid isPermaLink="false">https://medium.com/p/055defda3643</guid>
            <category><![CDATA[precision-fermentation]]></category>
            <category><![CDATA[future-food]]></category>
            <category><![CDATA[cellular-agriculture]]></category>
            <category><![CDATA[synthetic-biology]]></category>
            <dc:creator><![CDATA[Tarika Vijayaraghavan, Ph.D. ]]></dc:creator>
            <pubDate>Tue, 12 Nov 2024 20:11:07 GMT</pubDate>
            <atom:updated>2024-10-02T21:23:56.263Z</atom:updated>
            <content:encoded><![CDATA[<p>..and some are already on retail shelves 🍔🥛</p><p>Precision fermentation utilizes tiny microbes to engineer food-grade proteins and fats using specific genetic codes.</p><p>While this technology is picking up at scale, it was already achieved as early as the <a href="https://www.fda.gov/about-fda/fda-history-exhibits/100-years-insulin">1920s with a blood glucose-controlling protein called insulin</a> and in the <a href="https://www.nature.com/scitable/knowledge/library/history-of-agricultural-biotechnology-how-crop-development-25885295/">1980s with the cheese-making enzyme chymosin</a>. Currently, all insulin and about 80% of dairy cheese are <a href="https://www.foodprocessing.com/product-development/article/33036674/precision-fermentation-comes-into-its-own">made possible</a> at scale using precision fermentation.</p><p>Impossible™️ Foods first pioneered its Impossible™️ Burger with a plant-based patty that “bleeds” just as a beef patty would. A bio-identical analogue of heme found in the roots of soybean plants (called <a href="https://faq.impossiblefoods.com/hc/en-us/articles/360019100553-What-is-soy-leghemoglobin-or-heme">soy leghemoglobin</a>) gives the burger a meaty mouthfeel. By utilizing molecular biology and fermentation principles, Impossible Foods was able to produce soy leghemoglobin at scale, which significantly enhanced consumer perception of plant-based meats and opened doors to further innovation in the food sector 🍔</p><p>Since 2014, over <a href="https://gfi.org/resource/alternative-protein-company-database/">60 ingredient companies</a> have emerged in the precision fermentation sector. I delved into ~50 such companies, and here is the breakdown of what they offer —</p><h4>Dairy proteins dominate the market 🥛</h4><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*9j5Ob5jZcoFSvwCZiICo3Q.png" /><figcaption><a href="https://tryboredcow.com/">Bored Cow</a> milk made from Perfect Day’s fermented whey protein. Courtesy: <a href="https://perfectday.com/newsroom/bored-cow-sprouts/">Perfect Day</a></figcaption></figure><p>Casein and whey make up a <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149046/#:~:text=Casein%20constitutes%20approximately%2080%25(,%2D%20micelle%20complexes%20(20).">majority</a> of the proteins found in dairy milk. Casein constitutes about 80% protein present in cow milk and is comprised of 4 subunits:</p><p><strong>Casein = ⍺-casein (S1), ⍺-casein (S2), β-casein and κ-casein.</strong></p><p>In contrast, whey is composed of 4 bioactive fractions:</p><p><strong>Whey = β-lactoglobulin, ⍺-lactalbumin, lactoferrin and glycomacropeptide</strong></p><p>Over 55% of the precision fermentation ingredient landscape today is dominated by dairy proteins, with companies that focus on combinations of casein protein subunits (<strong>⍺-casein (S1, S2), β-casein, κ-casein), </strong>or individual whey fractions <strong>(β-lactoglobulin, lactoferrin and ⍺-lactalbumin)</strong></p><p>Perfect Day led the way with its fermented β-lactoglobulin powder, which <a href="https://tomorrowfarms.co/">Tomorrow Farms</a> distributed and commercialized under the brand name Bored Cow.</p><p>Other categories within precision fermentation include <strong>ovalbumin</strong> (egg protein), <strong>palm oil and lipids</strong> (fats), <strong>brazzein and honey</strong> (sweeteners/sweet proteins), <strong>collagen, gelatin, and heme</strong> (animal-derived functional proteins), and <strong>chocolate and coffee</strong> (plant-derived compounds).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*rWtqiG4yKI8tZGgreAupkg.png" /><figcaption>Bubble chart categorizing current ingredient market landscape in precision fermentation. Data from 52 startups</figcaption></figure><p>Of the 30 companies actively working in the dairy protein category, about 19 produce casein proteins, some also producing whey (β-lactoglobulin or ⍺-lactalbumin). Companies actively working on lactoferrin are few (4), making lactoferrin a less competitive space.</p><p>✨ <em>A summary of lactoferrin and why it is an attractive investment opportunity can be found </em><a href="https://www.linkedin.com/posts/trove-biosciences_this-iron-awareness-week-lets-talk-iron-activity-7103425771083337728-eqyv?utm_source=share&amp;utm_medium=member_desktop"><em>here</em></a><em> and </em><a href="https://cdn.prod.website-files.com/641400f02d9306cbd4fb3f94/66f240edb25e36b31cfe8f26_Overview%20PF%20report%20(2).pdf"><em>here</em></a><em>, respectively.</em></p><h4>Runner-up: Palm oil 🌴</h4><p>Palm oil, a commodity product, is utilized in a <a href="https://supply-change.org/commodity/palm">plethora</a> of industry applications. Considering the <a href="https://www.nature.com/articles/s41477-020-00813-w">environmental implications</a> of palm oil production, there is a need for sustainably sourced palm oil alternatives. Since palm oil alternatives are primarily plant-based, precision fermentation-derived palm oil is becoming an attractive market sector.</p><p>Some notable companies in the fermented palm oil sector include: <a href="https://news.mit.edu/2023/clean-alternative-palm-oil-replacement-0622">C16 Biosciences</a>, <a href="https://www.thecellbase.com/news/nopalm-ingredients-secures-5m-to-scale-up-palm-oil-alternative">NoPalm Ingredients</a>, <a href="https://www.greyb.com/blog/colipi-precision-fermentation-technology/">Colipi</a> and <a href="https://cleanfood.group/news/lab-grown-palm-oil-alternative-step-closer-as-clean-food-group-secures-seed-financing-1">Clean Food Group</a>.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*fxtJku9vjjms2TfPed-j-Q.png" /><figcaption>Precision-fermented products category broken down by ingredients and companies.</figcaption></figure><h4><strong>Powered by Yeasts 🫧</strong></h4><p>The relationship between yeasts and food is an age-old tryst. From ancient bread-making to modern kombucha, fermenting yeast in the kitchen is a cakewalk.</p><p>For centuries, yeasts have been central to fermentation research, playing a key role in advancing microbial engineering. The yeast strain <em>Pichia pastoris</em> is a standard strain used in precision fermentation due to its scientifically established protocols, ease of engineering, and Generally Regarded As Safe (GRAS) regulatory status.</p><p>However, other microbial strains like the <em>E. coli </em>bacteria and filamentous fungi <em>Trichoderma reesei </em>are also favoured.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*azVF6WbcEnXWTy3Lzq-2sw.png" /><figcaption>Venn diagram depicting number of companies using a specific or combination of microbes</figcaption></figure><h4>TL;DR</h4><p>📍 Precision fermentation involves brewing microbes to produce specific ingredients in a fermenter.</p><p>📍 Upon surveying 50 startups across the precision fermentation food landscape, here are three takeaways —</p><ul><li>Dairy Protein makes up a large chunk of the market.</li><li>Ingredients like lactoferrin and palm oil might be viable opportunities for innovation and investments.</li><li>Most precision fermentation companies utilize yeasts for microbial engineering.</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/1*YFPKuj7gysBIi-_8zgwnDA.png" /></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=055defda3643" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bioengineered-systems/50-companies-are-brewing-the-future-of-food-055defda3643">50+ companies are brewing the future of food</a> was originally published in <a href="https://medium.com/bioengineered-systems">Bioengineered systems</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Lactoferrin is dubbed the✨wonder molecule✨]]></title>
            <link>https://medium.com/bioengineered-systems/5-things-to-know-about-lab-made-lactoferrin-b23bad2a7ba2?source=rss----8623283b878f---4</link>
            <guid isPermaLink="false">https://medium.com/p/b23bad2a7ba2</guid>
            <category><![CDATA[synthetic-biology]]></category>
            <category><![CDATA[future-food]]></category>
            <category><![CDATA[biotechnology]]></category>
            <category><![CDATA[precision-fermentation]]></category>
            <category><![CDATA[cellular-agriculture]]></category>
            <dc:creator><![CDATA[Tarika Vijayaraghavan, Ph.D. ]]></dc:creator>
            <pubDate>Tue, 12 Nov 2024 20:10:53 GMT</pubDate>
            <atom:updated>2024-12-20T22:47:28.624Z</atom:updated>
            <content:encoded><![CDATA[<p>Here are 5 things you need to know about this animal-based protein, which can now be made without animal intervention 🥛</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*sJXtt0HIcIfBMjKw" /><figcaption>Photo by <a href="https://unsplash.com/@grakozy?utm_source=medium&amp;utm_medium=referral">Greg Rakozy</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><p>Iron is essential for many body functions, including carrying oxygen in red blood cells.</p><p>However, free iron can cause damage through free radical production.</p><p>🥛 Enter lactoferrin, an iron-binding protein found in mammalian breast milk</p><p>​​Lactoferrin:</p><ul><li>Increases <a href="https://academic.oup.com/bbb/article-abstract/52/4/903/5965671">iron absorption</a></li><li>Prevents <a href="https://link.springer.com/article/10.1007/s00018-005-5372-0">microbial growth</a></li><li>Protects against <a href="https://www.sciencedirect.com/science/article/pii/S0022030210006752">breast cancer</a></li><li>Protects against <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC4315141/">neonatal sepsis</a></li><li>Improves <a href="https://www.sciencedirect.com/science/article/pii/S1756464623003419">gut health</a></li><li>Aids in <a href="https://www.mdpi.com/2079-9284/11/3/98">wound healing</a></li></ul><p>Lactoferrin is seeing significant demand in infant care, health care, biopharmaceutical applications, and the fitness and wellness sector.</p><p><strong><em>The problem?</em></strong></p><p><strong>👎 Low expression levels:</strong> It is expressed in <a href="https://cdnsciencepub.com/doi/abs/10.1139/o01-215">extremely low levels</a> in the body. Cows produce &lt;0.1 mg/mL, while breastfeeding humans can produce &lt;5 mg/mL of lactoferrin.</p><p>In a more technical sense, this poor expression can be attributed to</p><ul><li><a href="https://pubmed.ncbi.nlm.nih.gov/16936795/">Transcriptional regulation</a>: how is lactoferrin produced on a fundamental level?</li><li><a href="https://pubmed.ncbi.nlm.nih.gov/23333090/">Tissue-specific expression</a>: which cell type produces the most lactoferrin, and how can physiology affect lactoferrin production in different tissues?</li><li>Cellular microenvironment influences: are the cells getting adequate nutrients?</li></ul><p>💰 <strong>High cost: </strong>Pure lactoferrin sells for USD 400–3000/kg in the market, making it a highly premium ingredient. Today, it takes 10,000 litres of milk to produce and extract 1 kg lactoferrin (<strong>~0.1 g/l)</strong>, driving costs and creating a supply bottleneck.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*vfWjDZ-ZSE1IdxSXHbOmWw.png" /><figcaption>Graph depicting cost in USD per kg of lactoferrin. Capsule prices sourced from <a href="https://www.amazon.com/s?k=lactoferrin&amp;crid=2HKPXFO9ZSE2T&amp;sprefix=lactoferrin%2Caps%2C86&amp;ref=nb_sb_noss_1">Amazon</a> (US)</figcaption></figure><p>Fortunately, scientists have programmed microbes and cells to produce significantly higher lactoferrin concentrations for pharmaceutical and food-grade applications.</p><p><strong><em>Here are 5 things about animal-free recombinant lactoferrin to stay updated on this space —</em></strong></p><h4>1. Market and Technology</h4><p><a href="https://www.myhelaina.com/">Helaina</a>, <a href="https://www.turtletree.com/product/">TurtleTree Labs</a>, <a href="https://denovofoodlabs.com/home/">De Novo Food Labs</a>, <a href="https://www.allg.com/blog/the-best-of-nature-and-science-crafted-by-precision-fermentation">All G Foods</a> and <a href="https://wilkismilk.com/news/protein-report-israeli-bio-foodtech-company-wilk-announces-technological-breakthrough-human-lactoferrin-proteins-successfully-produced-in-laboratory-setting/">Wilk</a> are some of the prominent companies currently producing food-grade lactoferrin at the lab/pilot scale. Wilk produces human lactoferrin via mammary cells, whereas other companies engineer and ferment microbes (<em>Pichia pastoris,</em> mostly) to secrete and purify bovine and/or human lactoferrin.</p><h4>2. Academia suggests cost reduction techniques</h4><p><em>Aspergillus awamori, </em>a koji strain used in animal feed and enzyme production, serves as an excellent host for the production of lactoferrin, as documented in <a href="https://pubmed.ncbi.nlm.nih.gov/9188157/">this peer-reviewed research</a>. Researchers have demonstrated the capability of the strain in producing over 5g/L of recombinant lactoferrin while driving down the cost to &lt;$1/g (&gt;2x cost reduction compared to conventional lactoferrin). Plant molecular farming is another promising platform to express high levels of recombinant lactoferrin, although the unit economics are still on the higher end of the spectrum (<a href="https://pubmed.ncbi.nlm.nih.gov/16145832/">$5.9 per 1g</a> of lactoferrin).</p><h4>3. Investments</h4><p>The five companies listed above have collectively secured over 160 million USD since 2019 to produce recombinant lactoferrin.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*97wG5VpKV1eqUdnMV_UGNA.png" /><figcaption>The investment landscape — recombinant lactoferrin</figcaption></figure><h4>4. Regulations</h4><p>In November 2024, All G became the world’s <a href="https://www.allg.com/newsroom/all-g-secures-world-first-china-approval-to-sell-synthetic-pink-gold-dairy-protein-lactoferrin">first company</a> to attain regulatory approval in China for its recombinant bovine Lactoferrin (rLF). Shortly after, in December 2024, All G announced that it has also received a self-affirmed <a href="https://www.greenqueen.com.hk/all-g-bovine-lactoferrin-self-affirmed-gras-us-precision-fermentation/#:~:text=The%20Australian%20precision%20fermentation%20startup,Jan%20Pacas%20tells%20Green%20Queen.">GRAS</a> (generally regarded as safe) status, which takes it a step closer to selling its rLF in the US market.</p><p>TurtleTree Labs has also achieved a <a href="https://www.prnewswire.com/apac/news-releases/turtletree-obtains-the-worlds-first-self-gras-for-animal-free-lactoferrin-lf-now-approved-to-commercialize-in-the-us-301996148.html">self-affirmed GRAS</a> status and a <a href="https://www.greenqueen.com.hk/turtletree-vegan-certification-precision-fermentation-dairy-protein/">vegan certification</a> to bolster its go-to-market strategy for its bovine lactoferrin product (LF+).</p><h4>5. Dairy Industry Eyes Opportunity</h4><p>FrieslandCampina and Danone are placing their bets on recombinant lactoferrin. Dutch-based dairy giant <a href="https://www.foodnavigator.com/Article/2024/03/21/frieslandcampina-invests-in-lactoferrin-made-by-precision-fermentation">FrieslandCampina</a> partnered with the synthetic biology platform TripleBar to produce sustainably sourced lactoferrin efficiently. <a href="https://www.greenqueen.com.hk/danone-wilk-cultured-breast-milk-investment/">Danone’s investment</a> in Wilk suggests a keen interest in producing high-value animal-free dairy proteins, including recombinant lactoferrin.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*6cX3yNdZSNv153E-nbMKiQ.png" /><figcaption>Market, commercial and technology landscape of food-grade recombinant lactoferrin</figcaption></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1000/1*YFPKuj7gysBIi-_8zgwnDA.png" /></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b23bad2a7ba2" width="1" height="1" alt=""><hr><p><a href="https://medium.com/bioengineered-systems/5-things-to-know-about-lab-made-lactoferrin-b23bad2a7ba2">Lactoferrin is dubbed the✨wonder molecule✨</a> was originally published in <a href="https://medium.com/bioengineered-systems">Bioengineered systems</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>